Modulation of Kv3 Subfamily Potassium Currents by the Sea Anemone Toxin BDS: Significance for CNS and Biophysical Studies

Shuk Yin M. Yeung,1 Dawn Thompson,1 Zhuren Wang,2 David Fedida,2 and Brian Robertson1

1Neuroscience Group, School of Biomedical Sciences, University of Leeds, Leeds LS2 9NQ, United Kingdom, and 2Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z3

Introduction

Neuronal excitability is determined substantially by the characteristics of voltage-gated K⁺ channels (Hodgkin and Huxley, 1952; Hille, 2001). Clear identification of which K⁺ channel subtype determines particular physiological properties is crucial to understanding neuronal integration but also for selective therapeutic strategies. The Kv3 pharmacological and biophysical fingerprint [remarkably fast activation and deactivation, high threshold (Rudy et al., 1999)] mirrors certain neuronal K⁺ currents (Brew and Forsythe, 1995; Perney and Kaczmarek, 1997; Erisir et al., 1999; Southan and Robertson, 2000; Lien and Jonas, 2003), and, in many CNS neurons, a “fast spiking” phenotype is conferred by Kv3 channels (Martina et al., 1998; Wang et al., 1998; Rudy and McBain, 2001; Lien and Jonas, 2003). However, key issues remain; for example, Kv3 activation can be up to 30 mV different between model cells and neurons. Disappointingly, Kv3 single-subunit knock-out mice showed modest changes in firing frequency and overall phenotype (Ho et al., 1997), perhaps attributable to compensation (Porcello et al., 2002). Although the pharmacology of Kv3 channels is fairly distinctive [high sensitivity to 4-AP and tetraethylammonium (TEA)] (Rudy et al., 1999), there is a pressing need for highly selective tools to dissect out their roles in neuronal signaling.

Kv3.4 subunits have been implicated recently in responses to chronic hypoxia (Kaab et al., 2005) and, significantly, in the etiology of Alzheimer’s (Angulo et al., 2004) and Parkinson’s (Baranauskas et al., 2003) diseases, sparking considerable interest in Kv3.4 subunits as a therapeutic target for these major CNS disorders (Surmeier et al., 2004). Toxins provide the most powerful pharmacological tools to help unravel channel function in neurons, and selective subunit blockers might have utility in CNS diseases. Several toxins are available for individual Kv1 subunits and useful in identifying the functions of low-threshold conductances (Geiger and Jonas, 2000; Southan and Robertson, 2000; Dodson et al., 2003; Ishikawa et al., 2003).

There is a shortage of Kv3 subfamily-specific toxins, but Diochot et al. (1998) reported that sea anemone toxins BDS-I and BDS-II (“blood depressing substance”) were highly specific blockers for Kv3.4 subunits in expression systems. This led to several groups using these toxins as selective antagonists for

Kv3 potassium channels, with their ultra-rapid gating and high activation threshold, are essential for high-frequency firing in many CNS neurons. Significantly, the Kv3.4 subunit has been implicated in the major CNS disorders Parkinson’s and Alzheimer’s diseases, and it is claimed that selectively targeting this subunit will have therapeutic utility. Previous work suggested that BDS toxins (“blood depressing substance,” from the sea anemone Anemonia sulcata) were specific blockers for rapidly inactivating Kv3.4 channels, and consequently these toxins are increasingly used as diagnostic agents for Kv3.4 subunits in central neurons. However, precisely how selective are these toxins for this important CNS protein? We show that BDS is not selective for Kv3.4 but markedly inhibits current through Kv3.1 and Kv3.2 channels. Inhibition comes about not by “pore block” but by striking modification of Kv3 gating kinetics and voltage dependence. Activation and inactivation kinetics are slowed by BDS-I and BDS-II, and VA for activation is shifted to more positive voltages. Alanine substitution mutagenesis around the S3b and S4 segments of Kv3.2 reveals that BDS acts via voltage-sensing domains, and, consistent with this, ON gating currents from nonconducting Kv3.2 are markedly inhibited. The altered kinetics and gating properties, combined with lack of subunit selectivity with Kv3 subunits, seriously affects the usefulness of BDS toxins in CNS studies. Furthermore, our results do not easily fit with the voltage sensor “paddle” structure proposed recently for Kv3 channels. Our data will be informative for experiments designed to dissect out the roles of Kv3 subunits in CNS function and dysfunction.

Key words: potassium channel; Kv3 channels; fast spiking; toxins; Parkinson’s disease; BDS

Received Jan. 31, 2005; revised July 28, 2005; accepted July 28, 2005.

The work was supported by Medical Research Council Grant G0602307 and Wellcome Trust Grant 060261 (B.R.). D.F. is supported by grants from The Heart and Stroke Foundation of British Columbia and Yukon and the Canadian Institutes of Health Research. We thank Annette Dolphin, Hanuhiro Higashida, and Bernardo Rudy for kindly furnishing clones and cells. Thanks also to Drs. Jim Deuchars and Neil Morris for helpful comments and Prof. David Colquhoun for discussions on curve fitting. Correspondence should be addressed to Brian Robertson, School of Biomedical Sciences, University of Leeds, The Worsley Building, Leeds LS2 9GQ, UK. E-mail: b.robertson@leeds.ac.uk.

Copyright © 2005 Society for Neuroscience 0270-6474/05/258735-11$15.00/0 DOI:10.1523/JNEUROSCI.2119-05.2005
Kv3.4 subunits in neuronal (Chabbert et al., 2001; Riazanski et al., 2001; Baranauskas et al., 2003; Brooke et al., 2004; Shevchenko et al., 2004) and non-neuronal (Abbott et al., 2001; Wang et al., 2004) preparations, assigning functional roles to this single subunit. We report here that BDS is not subunit selective but also inhibits Kv3.1 and Kv3.2 subunits. BDS toxins are gating modifiers, positively shifting $V_{1/2}$ for activation, reducing ON gating charge, and markedly slowing activation kinetics of Kv3 channels. (These results alone make complete subtraction of native K$^+$ currents invalid.) Using alanine substitution, we find that the S3b–S4 segments are important for BDS inhibition, consistent with several other toxin gating modifiers. Furthermore, because BDS inhibits closed Kv3 channels, it is not clear how the toxin reaches S3b–S4 regions buried deep in the membrane lipid, as the crystal structure of bacterial KvAP channels implies.

Materials and Methods

Cell culture. tsA201 cells were a kind gift of Prof. Annette Dolphin (University College London, London, UK) and were used as the expression system for transient transfections of Kv3.2b and Kv3.4b channels. Cells were grown in 25 cm$^2$ tissue culture flasks (Nalge Nunc International, Hereford, UK) in MEM with 10% fetal bovine serum (FBS), 1% non-essential amino acids, and 1% penicillin/streptomycin antibiotic solution and were maintained as above. Both cell lines were passaged every 3–4 d.

Kv3 channel transfection. tsA201 cells were plated onto 35-mm-diameter Petri dishes at an approximate density of $1 \times 10^5$ cells/ml and transfected the same day. Wild-type rat Kv3.2b and human Kv3.4b clones were kind gifts of Prof. Bernardo Rudy (New York University, New York, NY), which were introduced into the cells using LipofectAMINE PLUS (Invitrogen, Paisley, UK). Transfected cells were reseeded the next day and incubated for at least 2 h before use in electrophysiological experiments. As a marker for successfully transfected cells, green fluorescing protein was cotransfected with target Kv3 cDNA. More than 75% of fluorescing cells expressed the Kv3 current of interest.

For the gating current experiments, a nonconducting mutant (NCM) rat Kv3.2b channel P468W was transfected into the incubator before experiments and placed in a superfusion chamber (volume of 250 $\mu$L) containing the bath solution at 22–23°C. Current recording and data analysis were performed using an Axopatch 200A amplifier and pClamp 6 software (Axon Instruments, Union City, CA). Capacitance compensation and leak subtraction using a P/6 protocol from a holding potential of $-100$ mV were routinely used during gating current recordings. Data were sampled at 10–50 kHz and filtered at 2–10 kHz. All $G_{max}$ and $Q_{off}$ measurements were obtained by integrating the ON- or OFF-going currents during 12 ms depolarizations or repolarizations.

Solutions. The internal solution contained the following (in mM): 125 methylsulfonic acid (K$^+$ salt), 20 KCl, 4 ATP (Mg$^{2+}$ salt), 10 HEPES, 5 phosphocreatine (Na$^+$ salt), and 5 EGTA, pH 7.2 adjusted with NaOH. This solution was stored at $-20^\circ$C and thawed and filtered at 0.1 $\mu$m immediately before use. The external solution contained the following (in mM): 135 NaCl, 5 KCl, 2 CaCl$_2$, 2 MgCl$_2$, 25 glucose, and 10 HEPES, pH 7.4 adjusted with NaOH. For gating current recordings from HEK 293 cells, patch pipette solution contained the following (in mM): 135 N-methyl-$n$-glucamine, 5 EGTA, 1 MgCl$_2$, and 10 HEPES, pH 7.2 adjusted with HCl. For these experiments, the external solution contained the following (in mM): 135 NMG$^+$, 10 HEPES, 1 MgCl$_2$ and 1 CaCl$_2$, pH 7.4 adjusted with HCl. All salts were ANALAR or equivalent grade and obtained from BDH Chemicals (Poole, UK) or Sigma (St. Louis, MO). BDS toxins, isolated from Anemone sulcata, were obtained from Alomone Labs (Jerusalem, Israel). BDS and other agents were applied externally via bath superfusion. Concentration–response curves were constructed using the following logistic (Hill) equation: response = maximum response/[(IC$_{50}$/concentration)], using the program Origin (version 5.0; Microcal Software, Northampton, MA). Calculated fits were confirmed independently by use of the program CFFIT from Prof. David Colquhoun (University College London; http://www.ucl.ac.uk/Pharmacology/dcpp59.html#cfit). The CFFIT program is a general purpose curve-fitting program that allows weighted least-squares fitting and calculation of errors. We found little difference in IC$_{50}$ or overall fits between these two methods. Results are expressed as mean $\pm$ SEM, and $n$ is the number of cells. Two-tailed unpaired Student’s t tests, unless otherwise stated, were used to calculate statistical significance. Results were considered significant at the $p < 0.05$ level.

Results

The sea anemone toxin BDS inhibits Kv3.4

BDS toxins were originally reported as selective, high-affinity blockers for homomeric Kv3.4 channels in mammalian and oocyte expression systems (Diochot et al., 1998). We sought to re-explore the selectivity of BDS toxins after somewhat ambiguous results with BDS-I and BDS-II in a CNS slice preparation known to be richly endowed with Kv3.4 subunits (N. P. Morris and B. Robertson, unpublished observations). We carefully examined the selectivity and potency of BDS-I and BDS-II on homomeric Kv3 subunits expressed in mammalian cell lines. Control Kv3.4b currents in tsA201 cells exhibited both rapid activation and rapid inactivation characteristic of “A-type” potassium currents, as reported previously (for review, see Rudy et al., 1999) (Fig. 1).
Half-maximal activation of this conductance occurred at +15.1 ± 1.9 mV, with k of 11.2 ± 0.7 mV (both n = 12). Time constants for activation and inactivation from 12 cells at +40 mV were 1.3 ± 0.1 and 10.9 ± 0.8 ms, respectively; all of these values are within the published range (Rudy et al., 1999). Application of 500 nM BDS-I inhibited Kv3.4 to approximately half (44.1 ± 3.9% of peak amplitude at +40 mV; n = 9). Onset of block (~20 s) was rapid, achieving stable inhibition after ~1 min (Fig. 1A, inset); BDS inhibition was completely reversed during washout. These data confirm the findings of Diochot et al. (1998), although both BDS isoforms proved less potent in our experiments (see below) and had faster on and off rates for inhibition. Conductance–voltage (G–V) relationships for Kv3.4 were measured (Fig. 1B), and, from single Boltzmann fits to these curves, $V_{1/2}$ and k were +10.7 ± 3 and 10.8 ± 1 mV (n = 3) in control; in 500 nM BDS-I, $V_{1/2}$ was shifted ~16 mV positive (to +26.9 ± 1 mV), with no effect on k (both n = 3). Importantly, BDS not only shifted the activation curve of Kv3.4 but also changed time course of activation and inactivation (Fig. 1A), slowing both approximately twofold. At +40 mV, $\tau_{\text{act}}$ changed from 1.7 ± 0.1 ms in control to 3.2 ± 0.3 ms (n = 7), whereas $\tau_{\text{inact}}$ changed from 10.3 ± 0.5 to 19.6 ± 2.4 ms (n = 5) in 500 nM BDS-I. The rightward shift in activation and slowed kinetics suggested that BDS was not acting like a simple “pore blocker” of Kv3.4 currents, but a “gating modifier” [compare for example, the actions of HaTX on Kv2.1 (Swartz and MacKinnon, 1997a)]. Given the strong sequence homology of Kv3 subfamily channels in regions considered to be important for gating (Coetzee et al., 1999), we tested whether these effects were restricted to Kv3.4 subunits or applied to other members of the Kv3 subfamily.

**BDS toxins also modify Kv3.1 and Kv3.2 channels**

Fibroblasts stably expressing Kv3.1a subunit homomeric channels produced large-amplitude currents that were inhibited by BDS-I and BDS-II in a concentration-dependent manner (Fig. 2A, B). Again, inhibition by both toxin isoforms was rapid in onset (limited only by perfusion time to cells) and reversible. Inhibition of peak current amplitudes was measured at +40 mV, and IC$_{50}$ values were 220 nM for BDS-I and 750 nM for BDS-II (slope factors of 1.1 and 0.8, respectively). Fitting fractional inhibition of Kv3.1 by BDS using steps to more negative voltages (0 mV) (Swartz and MacKinnon, 1997) proved unsuccessful, because at very low BDS concentrations, no inhibition [or even modest enhancement (Fig. 2C)] of current was observed. Additionally, our concentration–response data were very poorly fitted by fourth-order functions, as might be expected of gating modifier toxins binding to individual voltage sensors (see below). Unfortunately, concentrations at or above 3 μM BDS-I or BDS-II proved toxic to cells, preventing absolute determination of IC$_{50}$ values. However, taking the weights of the errors associated with each measurement into account, it is unlikely that there is a significant difference in inhibition between the two BDS isoforms (D. Colquhoun, personal communication). It is unlikely that 100% inhibition of Kv3 current with BDS would ever be observed because, with other K$^+$ channels and toxins (including gating modifiers, see below), residual current flow occurs at maximal toxin block; the molecular basis for this is not yet understood (Owen et al., 1997; Imredy and MacKinnon, 2000). Similar concentration-dependent inhibitory effects were observed with both BDS isoforms on Kv3.2b channels transiently expressed in tsA201 cells (data not shown). We point out that the concentration–response curve is model independent. The curve allows a close comparison (similar voltage step length and amplitudes) with the inhibition obtained by Diochot et al. (1998) and shows that, in our experiments, BDS is less potent. As we will see below, BDS has complex actions on Kv3 channel gating and has voltage dependence; therefore, IC$_{50}$ values will alter depending on the protocols used.

Figure 2, C and D, reveals that the inhibition by BDS-I and BDS-II is voltage dependent, being more marked at higher concentrations, in which they vary in effectiveness approximately fourfold over the voltage range tested. For example, 500 nM BDS-II inhibited Kv3.1a by 76.1 ± 5.9% (n = 9) at +10 mV but by only 18.3 ± 5.6% (n = 8) at +70 mV.

For further examination of the effects of these toxins, a convenient concentration of 500 nM BDS-I and BDS-II was selected,
BDS inhibition does not open channels

Voltage protocols that force KD3.1 and BDS-II reduced KD3.1 and KD3.2 currents over a large voltage range. It was of interest to determine whether these toxins similarly affected channels in a closed state. Control KD3.1 and KD3.2 currents were evoked by shifting from 500 mM KCl to 500 nM BDS-I or BDS-II. Changes in the amplitude of BDS inhibition were calculated from tail currents in 35 mM [K+]/H11006 (1.0 mM KCl). BDS-I and BDS-II toxins inhibited KD3.1 and KD3.2 channel currents. For instance, at 8738 â€” 45.3 ± 3.3% (n = 4) and KD3.2 by 48.1 ± 4.5% (n = 8). BDS-I and BDS-II toxins inhibited KD3.1 by 46.6 ± 2.9% (n = 4) and KD3.2 by 37.9 ± 3.7% (n = 4). This suggests that each BDS isoform is effective at inhibiting KD3 channels.

Figure 4 shows the control G-V curve for KD3.1 channels. In contrast, continuously opening the channels at high frequencies or interspersing stronger depolarizing pulses between deactivating steps did not appear to decrease BDS inhibition (data not shown), suggesting that once bound to the channel, BDS is not "knocked off" by voltage or greater K+ conductance. BDS toxins simply unmasked an endogenous voltage-gated K+ current (data not shown). Similarly, BDS toxins did not appear to inhibit KD3 channels under these conditions. The endogenous voltage-gated K+ current in KD3 channels is extremely rapidly, these values were measured from tail currents in 35 mM [K+]/H11006 (1.0 mM KCl). BDS-I and BDS-II toxins inhibited KD3.1 and KD3.2 channel currents. For instance, at 8738 â€” 45.3 ± 3.3% (n = 4) and KD3.2 by 48.1 ± 4.5% (n = 8). BDS-I and BDS-II toxins inhibited KD3.1 by 46.6 ± 2.9% (n = 4) and KD3.2 by 37.9 ± 3.7% (n = 4). This suggests that each BDS isoform is effective at inhibiting KD3 channels.
Table 1. Time constant of current activation for the fast ($\tau_{\text{fast}}$) and slow ($\tau_{\text{slow}}$) components of Kv3.1a and Kv3.2b channel currents in the absence and presence of 500 nM BDS-I and 500 nM BDS-II.

<table>
<thead>
<tr>
<th></th>
<th>$\tau_{\text{fast}}$ at +40 mV (ms)</th>
<th>$\tau_{\text{slow}}$ at +40 mV (ms)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Kv3.1a</td>
<td>Kv3.2b</td>
</tr>
<tr>
<td>Control</td>
<td>4.6 ± 0.9</td>
<td>2.3 ± 0.3</td>
</tr>
<tr>
<td>500 nM BDS-I</td>
<td>12.2 ± 1.7</td>
<td>9.6 ± 1.8</td>
</tr>
<tr>
<td>Fold change</td>
<td>3.1×</td>
<td>4.6×</td>
</tr>
<tr>
<td>Control</td>
<td>3.2 ± 0.9</td>
<td>1.8 ± 0.2</td>
</tr>
<tr>
<td>500 nM BDS-II</td>
<td>13.9 ± 3.9</td>
<td>10.2 ± 2.6</td>
</tr>
</tbody>
</table>
| Fold change   | 4.7×                              | 5.7×                              | 6.4×

Current activation was recorded at +40 mV and fitted with a double-exponential function. Time constants are for paired data.

The toxins slow activation and shift activation to more positive voltages, altering the energetics of $K^+$ channel activation. Alkaline scanning of the entire S1–S4 domains of Kv2.1 revealed that HaTX binds to a region between the latter part of S3 (S3b) and adjacent to the S3/S4 linker (Swartz and MacKinnon, 1997a; Li-Smerin and Swartz, 2000). Because of the strong similarities between HaTX and BDS effects, we aligned Kv2.3b and Kv2.1, making several alanine substitutions in proposed BDS recognition "patches." Cells containing Kv3.2b channels were chosen for these experiments because this was a transient transfection system allowing us to screen a number of mutants more easily. Two such mutants, mutant 2 and mutant 4 (although fluorescent after transfection) with amino acid substitutions in S4, yielded currents ($n = 7$ and $n = 10$ cells, respectively) that were indistinguishable from the endogenous currents of tsA201 cells, measured by current density and $G$–$V$ curves (data not shown). This was disappointing because corresponding amino acid changes in Kv2.1 channels reduced HaTX sensitivity twofold to fivefold, but clearly changes here in Kv3 channels may not be tolerated or expressed.

Table 1. Time constant of current activation for the fast ($\tau_{\text{fast}}$) and slow ($\tau_{\text{slow}}$) components of Kv3.1a and Kv3.2b channel currents in the absence and presence of 500 nM BDS-I and 500 nM BDS-II.

Determination of the amino acids required for BDS inhibition

We next sought to identify the regions important for BDS toxins inhibitory effects by site-directed mutagenesis, changing wild-type amino acids to alanine (Swartz and MacKinnon, 1997b). BDS alters Kv3 channels in a manner very similar to how HaTX affects Kv2.1 channels (Swartz and MacKinnon, 1997a,b); both toxins slow activation and shift activation to more positive voltages, altering the energetics of $K^+$ channel activation. Alkaline scanning of the entire S1–S4 domains of Kv2.1 revealed that HaTX binds to a region between the latter part of S3 (S3b) and adjacent to the S3/S4 linker (Swartz and MacKinnon, 1997a; Li-Smerin and Swartz, 2000). Because of the strong similarities between HaTX and BDS effects, we aligned Kv2.3b and Kv2.1, making several alanine substitutions in proposed BDS recognition "patches." Cells containing Kv3.2b channels were chosen for these experiments because this was a transient transfection system allowing us to screen a number of mutants more easily. Two such mutants, mutant 2 and mutant 4 (although fluorescent after transfection) with amino acid substitutions in S4, yielded currents ($n = 7$ and $n = 10$ cells, respectively) that were indistinguishable from the endogenous currents of tsA201 cells, measured by current density and $G$–$V$ curves (data not shown). This was disappointing because corresponding amino acid changes in Kv2.1 channels reduced HaTX sensitivity twofold to fivefold, but clearly changes here in Kv3 channels may not be tolerated or expressed.

As discussed above, BDS toxins inhibited Kv3.2b currents similarly to Kv3.1 currents. Data from four exemplar cells is shown in Figure 6. $Ai$ and $Aii$, in which 500 nM BDS-II shifted control Kv3.2b conductance from $V_{1/2}$ of +13.6 ± 1.48 mV ($k$ = 10.5 ± 0.7 mV) to $V_{1/2}$ of +30.4 ± 2.7 mV ($k$ = 10 ± 0.9 mV). We made a triple mutant (V330, G331, G334: mutant 1) of the S3b region of Kv3.2b (which aligns to I273, F274, E277 amino acids in Kv2.1), because this is an area that displayed the greatest reduction in the sensitivity of Kv2.1 to HaTX (Swartz and MacKinnon, 1997b). Mutant 1 constructs produced large, robust currents at all potentials examined (0 to 35 mV; correspondingly to Kv2.1 channels reduced HaTX sensitivity twofold to fivefold, but clearly changes here in Kv3 channels may not be tolerated or expressed.

As discussed above, BDS toxins inhibited Kv3.2b currents similarly to Kv3.1 currents. Data from four exemplar cells is shown in Figure 6. $Ai$ and $Aii$, in which 500 nM BDS-II shifted control Kv3.2b conductance from $V_{1/2}$ of +13.6 ± 1.48 mV ($k$ = 10.5 ± 0.7 mV) to $V_{1/2}$ of +30.4 ± 2.7 mV ($k$ = 10 ± 0.9 mV). We made a triple mutant (V330, G331, G334: mutant 1) of the S3b region of Kv3.2b (which aligns to I273, F274, E277 amino acids in Kv2.1), because this is an area that displayed the greatest reduction in the sensitivity of Kv2.1 to HaTX (Swartz and MacKinnon, 1997b). Mutant 1 constructs produced large, robust currents at all potentials examined (0 to 35 mV; correspondingly to Kv2.1 channels reduced HaTX sensitivity twofold to fivefold, but clearly changes here in Kv3 channels may not be tolerated or expressed.
as well as gating changes) depends on the integrity of the binding patch in the S3b region of Kv3.2b channels, in a region corresponding to the main HaTX-sensitive binding domain in Kv2.1 channels. Indeed, this region is significant for the interaction of several toxins with a number of ion channels (see Discussion).

In Kv2.1, changing the glutamic acid E277 in the S3b segment reduced HaTX sensitivity by 15-fold (Swartz and MacKinnon, 1997b). We were therefore interested to determine the contribution played by the nearby glutamic acid residue in Kv3.2b, which is five amino acids farther upstream in S3, adjacent to the binding patch identified in our experiments with mutant 1. Substituting this residue for alanine (E329A mutant) reduced BDS-I sensitivity (25.3 ± 2.5% inhibition at +40 mV; n = 6) (Fig. 6Ci), without a shift in the G–V curve (1 mV, with no change in k; n = 6) (Fig. 6Ci). The activation time constant at +40 mV was only a little slowed by 500 nM BDS-I being 9.5 ± 0.6 ms (n = 10). BDS exposure indicated by horizontal bar. Full recovery of the current was observed on washout of the toxin.

We made an additional triple mutant, this time in the S4 region of Kv3.2b, which is a region that contains a HaTX-sensitive patch on Kv2.1. Currents from this channel mutant (mutant 3: L347A, V350A, V353A) expressed robustly but now had a consid-
Figure 6. Actions of BDS-II on wild-type Kv3.2b channels and with mutations in their S3b region. The top panels show current recordings at +40 mV from tsA201 cells transiently expressing either wild-type Kv3.2b mutant 1 (triple substitution: V330A, G331A, G334A) or E329A mutant Kv3.2b channels, in both the absence and presence of 500 nM BDS-II. The bottom panels are corresponding normalized G–V plot fits with Boltzmann functions. A, BDS-II at 500 nM inhibited Kv3.2b currents similarly to Kv3.1 currents, with slowing of activation and reduction of peak current. $V_{1/2}$ for control currents was $+13.6 \pm 1.48$ mV ($k = 10.5 \pm 0.7$ mV; $n = 4$) and moved rightward to $+30.4 \pm 2.7$ mV ($k = 10 \pm 0.9$ mV; $n = 4$) in BDS-II. Bi, BDS had only modest effects on the triple mutant, as shown in this example trace obtained with activating steps to −80 mV. Overlap of triple mutant 1 currents were significantly less than wild-type Kv3.2b channel currents as observed on comparison of the conductance–voltage curves, and a negligible shift in $V_{1/2}$ ($1 \pm 1$ mV; $n = 5$, paired data) was observed. There was no significant change in $k$. C, The E329A mutation also reduced sensitivity to BDS-II with a similar insignificant change in $V_{1/2}$ (shift of $−0.4 \pm 1.2$ mV; $n = 6$, paired data).

Figure 7. BDS-II both inhibits and potentiates mutant 3 currents. Mutant 3 contains three point residue mutations, L347A, V350A, and V353A, in the Kv3.2b channel. A, Current recordings at −10 mV (i) and +40 mV (ii) from a single tsA201 cell transiently expressing mutant 3 Kv3.2b channel subunits, in the presence and absence of 500 nM BDS-II. Traces were obtained on steps from a holding potential of −80 mV. B, Time course of current potentiation by BDS (exposure indicated by horizontal bar) at a single test potential of +40 mV. Enhancement occurs rapidly and is fully reversible. C, Normalized G–V plots obtained over the whole voltage range from −80 to +80 mV fitted with Boltzmann functions for mutant 3 control (i). Application of 500 nM BDS-II (ii) results in a depolarizing shift of $23 \pm 2$ mV (control $V_{1/2} = 33 \pm 1$ mV; BDS-II $V_{1/2} = 10 \pm 2$ mV; slope factors, $9.7 \pm 0.6$ and $9.8 \pm 0.2$ mV, respectively; $n = 6$). Enhancement of conductance occurred over the voltage range beyond +10 mV.

erably hyperpolarized activation voltage $V_{1/2}$ of $−35$ mV negative to wild-type Kv3.2b ($V_{1/2}$ becoming $−30.6 \pm 1.3$ mV, $k = 9.8 \pm 0.5$ mV, $n = 24$; wild type, $V_{1/2}$ $4.8 \pm 0.7$ mV, $k = 7 \pm 0.2$ mV, $n = 30$). Activation rates were significantly faster in mutant 3 channels, especially at voltages below +40 mV; for example, control Kv3.2 currents had a $t_{1/2}$ of $15.4 \pm 1.0$ ms at $+10$ mV ($n = 26$), and mutant 3 had values of $2.0 \pm 0.1$ ms ($n = 6$) at the same potential. BDS had complex and intriguing effects on this mutant channel, as shown in Figure 7. BDS-II at 500 nM shifted the mutant 3 activation curve to depolarized values by +23 mV and slowed activation kinetics (by 7- to 11-fold, depending on voltage) (Fig. 7Ai,Aii). However, a remarkable “crossover” effect was observed, such that, at voltages below 0 mV, BDS inhibited mutant 3 current (Fig. 7Ai,C), but, at voltages positive to this, BDS enhanced the current (Fig. 7Aii,B,C). This unexpected result is seen dramatically in Figure 7B, in which instead of inhibiting mutant 3 Kv3.2 channels, BDS-II actually increases current at +40mV. Interestingly, the tarantula toxin a-grammotoxin-SIA also induces a crossover effect on the G–V curves of certain neuronal voltage-gated calcium currents (McDonough et al., 1997), with shifts in $V_{1/2}$ of the order of 100 mV. Our data provide additional evidence that BDS is not a simple pore-blocking toxin (because it is difficult to conceive how such a mechanism could increase current) but is a gating modifier.

Subsequently, mutant 3 channels were broken down into the corresponding single point mutant channels (L347A, mutant 3a; V350A, mutant 3b; and V353A, mutant 3c) to determine which amino acid residue conferred changes in current inhibition, enhancement, and changes in gating by BDS-II. None of the single mutants (Fig. 8) produced the dramatic hyperpolarizing change in the G–V curve ($V_{1/2}$ shifting some 35 mV more negative) seen with the triple mutant (Fig. 7Ai,C). $V_{1/2}$ with triple mutant (Fig. 7Ai,C) resulted in a depolarizing shift of $23 \pm 2$ mV (control $V_{1/2} = 33 \pm 1$ mV; BDS-II $V_{1/2} = 10 \pm 2$ mV; slope factors, $9.7 \pm 0.6$ and $9.8 \pm 0.2$ mV, respectively; $n = 6$). Enhancement of conductance occurred over the voltage range beyond +10 mV.
(between +13 and +25 mV, with little effect on k), and slowed activation rates. Interestingly, BDS-II inhibition at +40 mV for mutant 3a (L347A) was reduced compared with wild-type Kv3.2b (~16 vs 52%) (Fig. 8A, Aii, Aiii).

Taking the data from our mutagenesis experiments together, BDS effectiveness depends principally on the integrity of the amino acids in the S3b (329–334) and to a lesser degree on residues near the “top” of S4 (347–353) regions. From the recent x-ray structure of the archaeabacterial potassium channel KvAP (Jiang et al., 2003a,b), these regions form part of the voltage sensor paddle, which resides deep in the membrane lipid, positioned toward the intracellular solution when the channel is closed. We therefore examined whether inhibition by BDS showed “sideliness,” by including toxin in the recording pipette and looking for changes in current amplitude, kinetics, or voltage dependence of activation over time. With 500 nM BDS-II in the intracellular solution, we saw no changes in any parameter over several minutes recording (up to 15 min; n = 10), suggesting that this toxin needs to be applied extracellularly to be effective.

Measurement of gating currents to establish mechanisms of BDS action

To examine the hypothesis that BDS toxins were inhibiting Kv3 channels by altering the energetics of gating, we performed gating current measurements, because these give direct insight into the movements of gating charges in the voltage sensors of the channel. The effects of BDS-II on voltage sensor movement were studied by recording the gating currents in a non-conducting mutant Kv3.2b channel, P468W, which has almost no ionic currents. Figure 9, A and B, shows gating current recordings at +10 or +80 mV in the presence and absence of 1 mM BDS-II in the bath solution. The toxin dramatically reduced the amplitude of the ON-gating currents elicited by the depolarization regardless of the magnitude of depolarization, indicating that voltage sensor movement was significantly hindered. This is consistent with the slowing of current activation seen in ionic current experiments with BDS-II. A similar reduction of the OFF-gating current was observed in the presence of BDS-II after the pulse to +10 mV. However, after the +80 mV depolarization, 1 mM BDS-II only caused a minor reduction in the OFF-gating current (Fig. 9B). These data suggest that full sensor movement needed the greater depolarization and that the toxin did not affect the return of the moved voltage sensors. This interpretation was confirmed by measuring the voltage-dependent movement of the gating charge. The integral of the gating currents (Qon) or the subsequent repolarization (Qoff) was normalized and plotted against the membrane potential (Q–V relationships) (Fig. 9C). Notably, in the toxin-treated cells, we could only measure the Q–V relationship from the OFF-gating currents. As discussed above, the reduction of the OFF-
gating currents by 1 mV BDS-II was almost removed after a +80 mV depolarization. Depolarizations to +100 or +120 mV also resulted in the maximum OFF-gating charge.

In Figure 9C, it is clearly shown that the toxin shifted the voltage dependence of the movement of the gating charge to more depolarized potentials. In control cells, we measured the $Q-V$ relationships for both ON- and OFF-gating currents. The $V_{1/2}$ and $k$ were $-10 \pm 7$ and $20 \pm 2.5$ mV ($n = 3$) for the ON-gating currents, respectively, and $-12 \pm 1.5$ and $23 \pm 1$ mV ($n = 6$) for the OFF-gating currents, respectively. We found that the toxin shifted the $Q-V$ relationship for OFF-gating current to more depolarized voltages by $\sim 26$ mV, a value satisfyingly in line with our shifts in the conductance voltage curves (see above). This supports the idea that BDS-II binds to, and stabilizes, a resting state of the Kv3 channel voltage sensor.

Discussion

Unraveling the complex electrical properties of neurons and ultimately designing effective, selective, therapeutic agents for CNS disorders requires precise knowledge of their complement of ion channels and receptors. For voltage-gated channels, identification of particular subtypes has been aided remarkably by comparing biophysical and pharmacological fingerprints obtained from expression systems to native currents (Southan and Robert-son, 2000; Lien and Jonas, 2003), use of selective antibodies (Trimmer and Rhodes, 2004), and genetic manipulations (Espinosa et al., 2004), but each of these approaches is beset with problems. Subunit-selective toxins are extremely useful in telling us how a particular subunit contributes to shaping electrical con-ductances (Dodson et al., 2003). Nevertheless, toxin selectivity and mechanisms of inhibition need to be carefully established before firm conclusions can be drawn. BDS toxins have been widely used to elucidate the role of Kv3.4 subunits, which have been recently implicated in two major CNS diseases.

BDS toxins are not selective blockers of Kv3.4 subunits

The nearly unique gating properties of Kv3 subfamily channels make them the strongest candidates to allow neurons to generate rapid firing patterns (Du et al., 1996; Erisir et al., 1999; Rudy and McBain, 2001; Dodson et al., 2003; Lien and Jonas, 2003). Although Kv3 channels have hallmark high sensitivity to 4-AP and TEA (Coetzee et al., 1999), these compounds are poorly selective, indicating a need for more potent, subunit-selective agents. Diochot et al. (1998) reported that BDS selectively blocked Kv3.4 subunits, leaving other members of the Kv3 subfamily unaffected. We find that this is not the case, because both BDS isoforms similarly inhibit Kv3.1a and Kv3.2b channels. [Our IC$_{50}$ for BDS-I and BDS-II is higher than Diochot et al. (1998), being closer to a more recent study (Abbott et al., 2001).] Alone, this calls into question work that assigns a specific role for the Kv3.4 subunit in neurons. Because we also find that BDS toxins dramat-ically change Kv3 gating (activation rates, voltage dependence), “clean” subtractions of Kv3 current from mixed conductances will be difficult.

There has long been a discrepancy between $V_{1/2}$ of Kv3s in expression systems and their neuronal phenotype. Baranauskas et al. (2003) suggested that Kv3.4 subunits shift the $V_{1/2}$ of other Kv3 currents to physiologically relevant negative potentials, partly based on pharmacological separation with BDS. Our data do not support this conclusion because, under very similar conditions, our splice variant of Kv3.4 activates $\sim 26$ mV more positive than that used by Baranauskas et al. (2003). Here, Kv3.4b subunits activate $\sim 10$ mV more depolarized to Kv3.2b when expressed in the same cells, and all of the alternative spliced versions of Kv3 channels have similarly positive voltage dependence (B. Rudy, personal communication). Perhaps modulation of the channels by second-messenger systems (Atzori et al., 2000; Macica and Kaczmarek, 2001; Moreno et al., 2001), experimental differences, or association with accessory proteins, such as MiRP$_s$ (MinK-related peptides) (Abbott et al., 2001; Lewis et al., 2004), are responsible for such dramatic differences in activation voltage.

Importantly, because BDS blocks all Kv3 subunits tested here with similar effectiveness, one must be cautious in assigning a role for any one Kv3 subfamily member using this toxin. Given the almost 100% sequence identity between all four Kv3 subfam-ily members in the regions we identify as being important for BDS action, it is not surprising that BDS inhibits Kv3.1 and Kv3.2 channels; we predict that Kv3.3 subunits will also show sensitiv-ity, as will heteromultimers. Our results therefore have important implications for the selective targeting of Kv3.4 subunits with BDS (or other knock-down strategies) in Parkinson’s disease (Baranauskas et al., 2003, Surmeier et al., 2004) or Alzheimer’s disease (Angulo et al., 2004); BDS will inhibit all Kv3 subunits, and our data do not support the proposed “threshold shifting” role of Kv3.4.

BDS toxins are gating modifiers, which bind to voltage-sensing regions of Kv3 channels

The actions of BDS-I and BDS-II to slow Kv3 channel activation rate and shift the G–V curve more depolarized are strongly remin-iscent of the effects of HaTX on Kv2.1 channels (Schwartz and MacKinnon, 1997a,b; Lee et al., 2003), in which only mutations in S3b and N-terminal part of S4 segments significantly altered HaTX binding affinity. We have similarly identified some single amino acid residues in this region that dramatically reduced BDS effects. Key residues in S3b are E329, V330, G331, and G334, whereas in S4, each single point mutant (mutant 3a, L347; mu-tant 3b, V350; mutant 3c, V353) had reduced BDS sensitivity. The largest reductions in BDS sensitivity were seen with E329 and L347 point mutants: BDS not only failed to inhibit peak current, but G–V curves and activation rate were unaffected, suggesting a common mechanism for all three effects. We interpret these results as being consistent with BDS interacting directly with residues in S3b and S4 of Kv3, which are part of the voltage sensor (Bezanilla, 2000), modifying the energetics of activation making channel opening more difficult. Such is the mechanism of action of several gating modifier toxins (Hille, 2001). Indeed, Schwartz and colleagues (Chuang et al., 1998; Li-Smerin and Swartz, 1998, 2000; Winterfield and Swartz, 2000) have shown that many gating modifier toxins (from a wide variety of species) interact with a similar region of voltage-sensing domains in voltage-gated Na$^+$, Ca$^{2+}$, and K$^+$ channels. This suggests a common evolu-tionary solution to targeting voltage-gated channels. Similar effects to BDS are seen with the marine snail toxin 6-bromo-2-mercaptotryptamine (BrMT) (Kelley et al., 2003; Sack et al., 2004), which also slows K$^+$ channel activation, positively shifts G–V curves, has no effect on deactivation, and modifies gating only from the extracellular side. Sack et al. (2004) suggest that BrMT slows early, but not late, activation steps in the activation pathway of Kv channels; we propose that BDS acts similarly to modify gating of Kv3 channels, via interaction with the voltage-
sensing paddle. Our conclusion is further strengthened by the results of our gating current experiments, which reveal that BDS-II markedly suppresses the ON-gating charge of noncon-ducting Kv3.2 channels, as well as shifting the voltage dependence of gating charge movement, supporting that the idea that BDS binds to, and stabilizes, a resting state of the voltage sensor of all Kv3 channels.

The elegant experiments of MacKinnon’s group suggest that these voltage-sensing domains reside in the membrane lipid moving upwards to gate Kv channels (Jiang et al., 2003a,b, 2004; Swartz, 2004). One problem with this model is that toxins have to partition into the membrane lipid to access their interaction sites (Lee et al., 2003). The tarantula toxin VSTX1 (voltage-sensor toxin 1) does partition into the lipid but this occurs very slowly (up to 1 h), producing a gradual inhibition of channels (Lee and MacKinnon, 2004). BDS acts within minutes, blocks channels in the closed state, and is ineffective when applied to the inside of cells. If BDS were partitioning into the lipid to reach its binding site, one would expect much slower alteration of channels, and it should act effectively both extracellularly and intracellularly; clearly, we need to know more about the interactions of toxins with membrane lipids and resting state paddles.

A strong argument against BDS being a classical open channel blocker is revealed by our triple (mutant 3) Kv3.2 channel, in which BDS caused crossover in the activation curve. It is hard to see how BDS could be a simple pore blocker at negative voltages but actually enhance current at positive potentials. Unfortunately, breaking mutant 3 down into the single amino acid mu-tants did not reveal the basis of this curious K− current enhance-ment, and neither did they shed light on the marked hyperpolarizing shift of the G-V curve in mutant 3 channels. [A marked hyperpolarizing shift in activation is also obtained with a single amino acid mutant in a homologous region in Kv2.1 channel (Li-Smerin et al., 2000).] There are examples of gating modi- fier toxins enhancing subtypes of Ca2+ channels (McDonough et al., 1997; Sidach and Mintz, 2002) likely through interaction with voltage-sensitive regions. This raises the tantalizing possibility that one might be able to design “agonist” properties into a gating modifier of Kv channels. Given the overwhelming impor-tance of Kv3 channels in controlling neuronal phenotype, along with their selective distribution in neurons, such compounds could have considerable therapeutic utility.

Conclusions
We show that BDS toxins are not subunit-selective blockers of Kv3.4 subunits but, through interaction with their conserved voltage-sensing domains, also inhibit other Kv3 subfamily mem-bers. This has implications for recent studies assigning a specific role for Kv3.4 in neuronal function and consequently suggestions for novel therapeutics, such as Parkinson’s therapies, based on this premise. BDS inhibition of Kv3 channels comes about by modification of channel gating, with slowed activation rates, and positive shifts of voltage dependence of gating currents and ionic conductance. These results show that BDS will be useful for iden-tifying the presence of all Kv3 channel subunits in neurons, but subtractions and extrapolations must be treated with consider-able caution.

References
Kelley WP, Wolters AM, Sack JT, Jockusch RA, Luchen JC, Williams ER,


